Lilly announces new study data on Inluriyo in metastatic breast cancer
The five-year survival rate for metastatic breast cancer is 30%
Read More
The five-year survival rate for metastatic breast cancer is 30%
Read MoreSome patients found the treatment reduced itch and sleep disturbance within just two days
Read MoreFind out which agencies came top and which agencies are among the big climbers in this year’s list
Read MoreThis autoimmune disease causes hair loss in both women and men, affecting 160 million people worldwide
Read MoreDec 17, 2025 | News, Regulatory
Around one in five breast cancer cases are HER2-positive
Read MoreInterim results have shown over 60% clinical clearance in patients treated with SkinJect
Read MoreDec 16, 2025 | News, Regulatory
Symptoms of the rare disease include bleeding, eczema and frequent infections
Read MoreThe new platform could speed up testing while reducing the need for animal models
Read MoreThe five-year agreement includes a focus on R&D for Alzheimer’s disease
Read MoreA universal safety test for CGTs could reduce both costs and wait times for treatment
Read MoreDec 12, 2025 | News, Healthcare
The site is the third of four new US sites that Lilly has announced
Read MoreKT-621 could become a first-in-class, once-a-day oral treatment
Read More
